UY37146A - Ligandos de direccionamiento para compuestos terapéuticos - Google Patents
Ligandos de direccionamiento para compuestos terapéuticosInfo
- Publication number
- UY37146A UY37146A UY0001037146A UY37146A UY37146A UY 37146 A UY37146 A UY 37146A UY 0001037146 A UY0001037146 A UY 0001037146A UY 37146 A UY37146 A UY 37146A UY 37146 A UY37146 A UY 37146A
- Authority
- UY
- Uruguay
- Prior art keywords
- compounds
- targeting ligands
- therapeutic compounds
- therapeutic
- expression
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 230000001225 therapeutic effect Effects 0.000 title abstract 3
- 230000014509 gene expression Effects 0.000 abstract 3
- 239000003446 ligand Substances 0.000 abstract 3
- 230000008685 targeting Effects 0.000 abstract 3
- 108091030071 RNAI Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000009368 gene silencing by RNA Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 210000005229 liver cell Anatomy 0.000 abstract 1
- 238000010200 validation analysis Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662304652P | 2016-03-07 | 2016-03-07 | |
| US201662370754P | 2016-08-04 | 2016-08-04 | |
| US201662426916P | 2016-11-28 | 2016-11-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY37146A true UY37146A (es) | 2017-09-29 |
Family
ID=59723428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001037146A UY37146A (es) | 2016-03-07 | 2017-03-07 | Ligandos de direccionamiento para compuestos terapéuticos |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US10246709B2 (enExample) |
| EP (1) | EP3426261A4 (enExample) |
| JP (4) | JP6983797B2 (enExample) |
| KR (3) | KR102348425B1 (enExample) |
| CN (2) | CN113797348A (enExample) |
| AU (3) | AU2017229469B2 (enExample) |
| BR (1) | BR112018068230B1 (enExample) |
| CA (1) | CA3011946A1 (enExample) |
| IL (3) | IL296377A (enExample) |
| JO (2) | JOP20170057B1 (enExample) |
| MX (3) | MX2018009854A (enExample) |
| TW (3) | TWI783434B (enExample) |
| UY (1) | UY37146A (enExample) |
| WO (1) | WO2017156012A1 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201620526A (zh) | 2014-06-17 | 2016-06-16 | 愛羅海德研究公司 | 用於抑制α－１抗胰蛋白酶基因表現之組合物及方法 |
| JOP20160211B1 (ar) | 2015-10-01 | 2021-08-17 | Arrowhead Pharmaceuticals Inc | تراكيب وأساليب لتثبيط تعبير جيني للـ lpa |
| US10246709B2 (en) * | 2016-03-07 | 2019-04-02 | Arrowhead Pharmaceuticals, Inc. | Targeting ligands for therapeutic compounds |
| CA3023764A1 (en) | 2016-06-06 | 2017-12-14 | Arrowhead Pharmaceuticals, Inc. | 5'-cyclo-phosphonate modified nucleotides |
| JOP20190015A1 (ar) | 2016-08-04 | 2019-02-04 | Arrowhead Pharmaceuticals Inc | عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب |
| JP6989521B2 (ja) | 2016-09-02 | 2022-01-05 | アローヘッド ファーマシューティカルズ インコーポレイテッド | 標的化リガンド |
| UY37565A (es) | 2017-01-10 | 2018-07-31 | Arrowhead Pharmaceuticals Inc | Agentes de iarn alfa-1 antitripsina (aat), composiciones que incluyen agentes de iarn aat y métodos de uso |
| EP3573623B1 (en) | 2017-01-30 | 2026-03-04 | Arrowhead Pharmaceuticals, Inc. | Compositions and methods for inhibition of factor xii gene expression |
| TN2020000039A1 (en) | 2017-09-11 | 2021-10-04 | Arrowhead Pharmaceuticals Inc | Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3) |
| PE20201287A1 (es) | 2017-09-14 | 2020-11-24 | Arrowhead Pharmaceuticals Inc | Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso |
| JP7473472B2 (ja) | 2017-10-17 | 2024-04-23 | アローヘッド ファーマシューティカルズ インコーポレイテッド | アシアロ糖タンパク質受容体１の発現を阻害するためのＲＮＡｉ剤および組成物 |
| IL281597B1 (en) * | 2018-09-19 | 2026-05-01 | Arrowhead Pharmaceuticals Inc | RNAI agents for suppressing 17 beta-HSD type 13 expression, (HASD17B13), their compositions and uses |
| CN111377985B (zh) * | 2018-12-29 | 2023-11-10 | 苏州瑞博生物技术股份有限公司 | 化合物和缀合物及其制备方法和用途 |
| EP3980540A4 (en) | 2019-06-06 | 2023-11-01 | Arrowhead Pharmaceuticals, Inc. | METHOD FOR TREATING ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) |
| US20220305117A1 (en) | 2019-06-18 | 2022-09-29 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai |
| AU2020301419B2 (en) | 2019-06-25 | 2026-03-19 | Amgen Inc. | Purification methods for carbohydrate-linked oligonucleotides |
| AU2020340987B2 (en) | 2019-09-03 | 2026-02-12 | Arcturus Therapeutics, Inc. | Asialoglycoprotein receptor mediated delivery of therapeutically active conjugates |
| GB2627644B (en) * | 2020-03-04 | 2024-11-20 | Verve Therapeutics Inc | Method for the preparation of GalNAc-lipid nanoparticle |
| JP2023519215A (ja) * | 2020-03-23 | 2023-05-10 | アムジエン・インコーポレーテツド | 化学修飾核酸に対するモノクローナル抗体及びその使用 |
| BR112022019241A2 (pt) | 2020-03-26 | 2022-11-16 | Arrowhead Pharmaceuticals Inc | Agentes de rnai para inibição da expressão de pnpla3, composições farmacêuticas dos mesmos e métodos de uso |
| US20230250125A1 (en) | 2020-04-01 | 2023-08-10 | Janssen Biopharma, Inc. | Nucleic acid polymers |
| US20230321284A1 (en) * | 2020-04-10 | 2023-10-12 | St. Marianna University School Of Medicine | Compound, contrast agent, and method for producing compound |
| WO2021254360A1 (zh) * | 2020-06-16 | 2021-12-23 | 上海拓界生物医药科技有限公司 | 一种碳水化合物分子簇及其制备方法和医药用途 |
| JP7846095B2 (ja) | 2020-09-15 | 2026-04-14 | アローヘッド ファーマシューティカルズ インコーポレイテッド | Ｚ－ａａｔタンパク質のレベルを低下させる方法 |
| CA3199678A1 (en) | 2020-11-05 | 2022-05-12 | Amgen Inc. | Methods for treating atherosclerotic cardiovascular disease with lpa-targeted rnai constructs |
| BR112023012377A2 (pt) | 2020-12-23 | 2023-10-24 | Flagship Pioneering Innovations Vi Llc | Composições de trems modificadas e usos das mesmas |
| EP4326334A1 (en) | 2021-04-23 | 2024-02-28 | GanNA Bio, Inc. | Glycan modified nucleic acids, methods of preparation, and therapeutic uses |
| US11549112B1 (en) | 2021-06-21 | 2023-01-10 | Arrowhead Pharmaceuticals, Inc. | RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use |
| EP4365290A1 (en) * | 2021-07-02 | 2024-05-08 | Tuojie Biotech (Shanghai) Co., Ltd. | Nucleic acid ligand and conjugate thereof, and preparation method therefor and use thereof |
| EP4380576A4 (en) | 2021-08-03 | 2026-04-29 | Verve Therapeutics Inc | RNA TARGETED COMPOSITIONS AND ADMINISTRATION METHODS |
| CN114703184B (zh) * | 2022-03-11 | 2024-06-18 | 厦门甘宝利生物医药有限公司 | Lpa抑制剂及其用途 |
| US20250283089A1 (en) | 2022-04-08 | 2025-09-11 | Arrowhead Pharmaceuticals, Inc. | Treatment of a non-alcoholic fatty liver disease |
| CN119562958A (zh) * | 2022-05-02 | 2025-03-04 | 安进公司 | 用于制备nag-25碳水化合物靶向部分及其中间体的方法 |
| WO2023233290A1 (en) | 2022-05-31 | 2023-12-07 | Janssen Sciences Ireland Unlimited Company | Rnai agents targeting pd-l1 |
| WO2023250112A1 (en) | 2022-06-22 | 2023-12-28 | Flagship Pioneering Innovations Vi, Llc | Compositions of modified trems and uses thereof |
| JP2026511018A (ja) | 2023-03-21 | 2026-04-10 | アローヘッド ファーマシューティカルズ インコーポレイテッド | 補体因子Ｂ（ＣＦＢ）の発現を阻害するためのＲＮＡｉ剤、その医薬組成物、及び使用方法 |
| AU2024280186A1 (en) | 2023-05-31 | 2025-12-04 | Tuojie Biotech (Shanghai) Co., Ltd. | Dsrna targeting lpa and use thereof |
| WO2025021831A1 (en) | 2023-07-24 | 2025-01-30 | Astrazeneca Ab | Multivalent cargo-carrying complexes and uses thereof |
| GB202311334D0 (en) | 2023-07-24 | 2023-09-06 | Astrazeneca Ab | Multivalent cargo-carrying complexes and uses thereof |
| GB202311324D0 (en) | 2023-07-24 | 2023-09-06 | Astrazeneca Ab | Multivalent cargo-carrying complexes and uses thereof |
| WO2025038661A1 (en) | 2023-08-14 | 2025-02-20 | Arrowhead Pharmaceuticals, Inc. | Oligonucleotide synthesis methods |
| WO2025042786A1 (en) | 2023-08-18 | 2025-02-27 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising circular polyribonucleotides and uses thereof |
| WO2025049773A1 (en) | 2023-08-30 | 2025-03-06 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for inhibiting expression of inhibin subunit beta e (inhbe), pharmaceutical compositions thereof, and methods of use |
| WO2025074157A1 (en) | 2023-10-06 | 2025-04-10 | Glaxosmithkline Intellectual Property (No.3) Limited | Treatment of a non-alcoholic fatty liver disease |
| TW202523695A (zh) | 2023-11-22 | 2025-06-16 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 用於治療非酒精性脂肪性肝病之方法及組成物 |
| US20250333742A1 (en) | 2024-04-25 | 2025-10-30 | Insitro, Inc. | Compositions and methods for treating metabolic dysfunction-associated steatotic liver disease |
| WO2025245188A2 (en) | 2024-05-21 | 2025-11-27 | Flagship Pioneering Innovations Vii, Llc | Methods of treating liver steatosis and non-alcoholic fatty liver disease |
Family Cites Families (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4751219A (en) | 1985-02-05 | 1988-06-14 | Nederlandse Centrale Organisatie Voor Toegepast-Natuur-Wetenschappelijk Onderzoek | Synthetic glycolipides, a process for the preparation thereof and several uses for these synthetic glycolipides |
| NL9201440A (nl) * | 1992-08-11 | 1994-03-01 | Univ Leiden | Triantennaire clusterglycosiden, hun bereiding en toepassing. |
| US6908903B1 (en) | 1994-12-07 | 2005-06-21 | Aletheon Pharmaceuticals, Inc. | Cluster clearing agents |
| US6172045B1 (en) | 1994-12-07 | 2001-01-09 | Neorx Corporation | Cluster clearing agents |
| US20030119724A1 (en) | 1995-11-22 | 2003-06-26 | Ts`O Paul O.P. | Ligands to enhance cellular uptake of biomolecules |
| JP2000501414A (ja) | 1995-11-22 | 2000-02-08 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 生体分子の細胞取り込みを高めるリガンド |
| US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
| EP0950665A4 (en) | 1996-09-26 | 2004-05-06 | Ajinomoto Kk | PHYSIOLOGICALLY ACTIVE MODIFIED PROTEINS AND DRUG COMPOSITIONS CONTAINING THEM |
| US6300319B1 (en) | 1998-06-16 | 2001-10-09 | Isis Pharmaceuticals, Inc. | Targeted oligonucleotide conjugates |
| EP1619210A1 (en) * | 1998-10-30 | 2006-01-25 | Daiichi Pharmaceutical Co., Ltd. | DDS compounds and method for assaying the same |
| US6383812B1 (en) | 1999-05-28 | 2002-05-07 | Academia Sinica | Anti liver disease drug R-YEEE and method of synthesizing branched galactose-terminal glycoproteins |
| US8541548B2 (en) | 1999-06-07 | 2013-09-24 | Arrowhead Madison Inc. | Compounds and methods for reversible modification of biologically active molecules |
| US20080281041A1 (en) | 1999-06-07 | 2008-11-13 | Rozema David B | Reversibly Masked Polymers |
| US7491805B2 (en) | 2001-05-18 | 2009-02-17 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| US20070026394A1 (en) | 2000-02-11 | 2007-02-01 | Lawrence Blatt | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies |
| US7833992B2 (en) | 2001-05-18 | 2010-11-16 | Merck Sharpe & Dohme | Conjugates and compositions for cellular delivery |
| ATE450621T2 (de) | 2000-03-30 | 2009-12-15 | Whitehead Biomedical Inst | Mediatoren von rns-interferenz, die rns- sequenzspezifisch sind |
| WO2002043771A2 (en) | 2000-12-01 | 2002-06-06 | Cell Works Inc. | Conjugates of glycosylated/galactosylated peptide |
| KR100872437B1 (ko) | 2000-12-01 | 2008-12-05 | 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. | Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자 |
| WO2002085908A1 (en) | 2001-04-24 | 2002-10-31 | Purdue Research Foundation | Folate mimetics and folate-receptor binding conjugates thereof |
| US7109165B2 (en) | 2001-05-18 | 2006-09-19 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| EP1572067A4 (en) | 2001-05-18 | 2009-05-13 | Sirna Therapeutics Inc | CONJUGATES AND COMPOSITIONS FOR CELLULAR RELEASE |
| US20030148928A1 (en) | 2001-07-20 | 2003-08-07 | Leonid Beigelman | Enzymatic nucleic acid peptide conjugates |
| US7439043B2 (en) | 2001-10-10 | 2008-10-21 | Neose Technologies, Inc. | Galactosyl nucleotide sugars |
| US20100240730A1 (en) | 2002-02-20 | 2010-09-23 | Merck Sharp And Dohme Corp. | RNA Interference Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (siNA) |
| AU2003260289A1 (en) | 2002-09-11 | 2004-04-30 | Santaris Pharma A/S | Modified pna molecules |
| WO2004080406A2 (en) | 2003-03-07 | 2004-09-23 | Alnylam Pharmaceuticals | Therapeutic compositions |
| AU2004227414A1 (en) | 2003-04-03 | 2004-10-21 | Alnylam Pharmaceuticals | iRNA conjugates |
| US7851615B2 (en) | 2003-04-17 | 2010-12-14 | Alnylam Pharmaceuticals, Inc. | Lipophilic conjugated iRNA agents |
| JP4597976B2 (ja) | 2003-04-17 | 2010-12-15 | アルナイラム ファーマシューティカルズ インコーポレイテッド | 修飾ｉＲＮＡ剤 |
| US7723509B2 (en) | 2003-04-17 | 2010-05-25 | Alnylam Pharmaceuticals | IRNA agents with biocleavable tethers |
| JPWO2004101619A1 (ja) | 2003-05-15 | 2006-10-26 | 塩野義製薬株式会社 | 機能的糖ペプチドの合理的設計および合成 |
| JP5192234B2 (ja) | 2004-08-10 | 2013-05-08 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | 化学修飾オリゴヌクレオチド |
| US20090203132A1 (en) | 2004-09-09 | 2009-08-13 | Swayze Eric E | Pyrrolidinyl groups for attaching conjugates to oligomeric compounds |
| US20060148740A1 (en) | 2005-01-05 | 2006-07-06 | Prosensa B.V. | Mannose-6-phosphate receptor mediated gene transfer into muscle cells |
| JP2008527993A (ja) | 2005-01-24 | 2008-07-31 | アヴァリス・アクチエボラーグ | 特異性及び送達の改善のためのｓｉＲＮＡ分子、ｓｈＲＮＡ分子又はアンチセンス分子及び機能的実体を含む複合体 |
| BRPI0715375A2 (pt) * | 2006-08-18 | 2013-06-18 | Hoffmann La Roche | policonjugados para distribuiÇço in vivo de polinucleotÍdeos |
| US8658211B2 (en) | 2006-08-18 | 2014-02-25 | Arrowhead Madison Inc. | Polyconjugates for in vivo delivery of polynucleotides |
| EP2604283A1 (en) | 2007-02-16 | 2013-06-19 | KTB Tumorforschungsgesellschaft mbH | Receptor And Antigen Targeted Prodrug |
| CA2685127C (en) | 2007-04-23 | 2019-01-08 | Alnylam Pharmaceuticals, Inc. | Glycoconjugates of rna interference agents |
| CN102006890A (zh) | 2007-12-04 | 2011-04-06 | 阿尔尼拉姆医药品有限公司 | 靶向脂质 |
| CA2708171C (en) | 2007-12-04 | 2018-02-27 | Alnylam Pharmaceuticals, Inc. | Folate conjugates |
| BRPI0907008A2 (pt) | 2008-01-31 | 2015-07-07 | Alnylam Pharmaceuticals Inc | Métodos otimizados para liberação de dsrna alvejando o gene pcsk9 |
| WO2009142822A2 (en) | 2008-03-26 | 2009-11-26 | Alnylam Pharmaceuticals, Inc. | 2-f modified rna interference agents |
| EP3604533A1 (en) | 2008-04-11 | 2020-02-05 | Arbutus Biopharma Corporation | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
| EP2342616A2 (en) | 2008-09-23 | 2011-07-13 | Alnylam Pharmaceuticals Inc. | Chemical modifications of monomers and oligonucleotides with cycloaddition |
| AU2009307677C1 (en) | 2008-10-20 | 2022-09-22 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of transthyretin |
| WO2010048585A2 (en) | 2008-10-24 | 2010-04-29 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and methods |
| EP4241767B1 (en) | 2008-11-10 | 2024-10-23 | Arbutus Biopharma Corporation | Novel lipids and compositions for the delivery of therapeutics |
| SG176553A1 (en) | 2009-05-05 | 2012-01-30 | Muthiah Manoharan | Lipid compositions |
| TR201811076T4 (tr) | 2009-06-10 | 2018-08-27 | Arbutus Biopharma Corp | Geliştirilmiş lipit formulasyonu. |
| WO2011005980A1 (en) * | 2009-07-09 | 2011-01-13 | Intradigm Corporation | Novel heterobifunctional polyethylene glycol reagents, their preparation and uses thereof |
| TWI458493B (zh) | 2009-09-25 | 2014-11-01 | Iner Aec Executive Yuan | 新穎肝標靶藥劑與合成方法 |
| TWI391144B (zh) | 2009-10-26 | 2013-04-01 | Iner Aec Executive Yuan | 一種定量肝殘餘功能的檢驗方法與其新穎肝受體造影檢驗藥劑 |
| TWI388338B (zh) | 2009-10-26 | 2013-03-11 | Iner Aec Executive Yuan | 對聚合醣鏈進行放射標誌以作為肝受體造影劑之方法 |
| WO2011072290A2 (en) | 2009-12-11 | 2011-06-16 | The Regents Of The University Of Michigan | Targeted dendrimer-drug conjugates |
| EP3023495B1 (en) | 2010-02-24 | 2019-05-08 | Arrowhead Pharmaceuticals, Inc. | Compositions for targeted delivery of sirna |
| EP2553019A1 (en) | 2010-03-26 | 2013-02-06 | Mersana Therapeutics, Inc. | Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof |
| US20130236968A1 (en) | 2010-06-21 | 2013-09-12 | Alnylam Pharmaceuticals, Inc. | Multifunctional copolymers for nucleic acid delivery |
| CA2812046A1 (en) | 2010-09-15 | 2012-03-22 | Alnylam Pharmaceuticals, Inc. | Modified irna agents |
| WO2012068187A1 (en) * | 2010-11-19 | 2012-05-24 | Merck Sharp & Dohme Corp. | Poly(amide) polymers for the delivery of oligonucleotides |
| BR112013013434A2 (pt) * | 2010-12-17 | 2016-08-16 | Arrowhead Res Corp | metade que tem por alvo modulador fármaco cinético em cacho de galactose para sirna |
| US8501930B2 (en) | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
| ES2605990T3 (es) | 2010-12-29 | 2017-03-17 | F. Hoffmann-La Roche Ag | Conjugados de molécula pequeña para la administración intracelular de ácidos nucleicos |
| US8642752B2 (en) | 2011-04-21 | 2014-02-04 | Isis Pharmaceuticals, Inc. | Modulation of Hepatitis B virus (HBV) expression |
| JP6165723B2 (ja) * | 2011-06-30 | 2017-07-19 | アローヘッド ファーマシューティカルズ インコーポレイテッド | Ｂ型肝炎ウイルスの遺伝子発現を阻害するための組成物および方法 |
| KR20140051357A (ko) | 2011-08-26 | 2014-04-30 | 애로우헤드 리서치 코오포레이션 | Ｉｎ Ｖｉｖｏ 핵산 전달용 폴리(비닐 에스테르) 고분자 |
| EP3640332A1 (en) | 2011-08-29 | 2020-04-22 | Ionis Pharmaceuticals, Inc. | Oligomer-conjugate complexes and their use |
| AU2012377385A1 (en) * | 2012-04-18 | 2014-01-23 | Arrowhead Research Corporation | Poly(acrylate) polymers for in vivo nucleic acid delivery |
| EP3358013B1 (en) | 2012-05-02 | 2020-06-24 | Sirna Therapeutics, Inc. | Short interfering nucleic acid (sina) compositions |
| TW201808342A (zh) | 2012-05-02 | 2018-03-16 | 喜納製藥公司 | 包含四ｇａｌｎａｃ之新穎結合物及傳送寡核苷酸之方法 |
| AR090905A1 (es) | 2012-05-02 | 2014-12-17 | Merck Sharp & Dohme | Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica |
| US9150602B2 (en) * | 2012-07-24 | 2015-10-06 | Atomic Energy Council, Institute Of Nuclear Energy Research | Precursor used for labeling hepatorcyte receptor and containing trisaccharide and diamide demercaptide ligand, method for preparing the same, radiotracer and pharmaceutical composition of the same |
| AU2013299717B2 (en) | 2012-08-06 | 2018-06-28 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugated RNA agents and process for their preparation |
| SG10201804331TA (en) | 2012-11-15 | 2018-07-30 | Roche Innovation Ct Copenhagen As | Oligonucleotide conjugates |
| WO2014118272A1 (en) | 2013-01-30 | 2014-08-07 | Santaris Pharma A/S | Antimir-122 oligonucleotide carbohydrate conjugates |
| US20150368642A1 (en) | 2013-01-30 | 2015-12-24 | Hoffmann-La Roche Inc. | Lna oligonucleotide carbohydrate conjugates |
| EP2992095B1 (en) | 2013-05-01 | 2019-01-09 | Regulus Therapeutics Inc. | Microrna compounds and methods for modulating mir-122 |
| CA2921162A1 (en) | 2013-05-01 | 2014-11-06 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| EP4039278A1 (en) | 2013-07-11 | 2022-08-10 | Alnylam Pharmaceuticals, Inc. | Oligonucleotide-ligand conjugates and process for their preparation |
| EP3610884B1 (en) | 2013-11-06 | 2021-08-18 | Merck Sharp & Dohme Corp. | Peptide containing conjugates for dual molecular delivery of oligonucleotides |
| AU2015252841B2 (en) | 2014-05-01 | 2020-03-19 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating growth hormone receptor expression |
| EP3151839A4 (en) * | 2014-06-06 | 2018-02-28 | Ionis Pharmaceuticals, Inc. | Compositions and methods for enhanced intestinal absorption of conjugated oligomeric compounds |
| TW201620526A (zh) | 2014-06-17 | 2016-06-16 | 愛羅海德研究公司 | 用於抑制α－１抗胰蛋白酶基因表現之組合物及方法 |
| WO2016001123A1 (en) | 2014-07-01 | 2016-01-07 | Gima Tt S.P.A. | Package for smoking articles |
| AU2015317958A1 (en) | 2014-09-15 | 2017-05-04 | Qubole, Inc. | Systems and methods for providing metadata-aware background caching in data analysis |
| US20170327524A1 (en) | 2014-10-10 | 2017-11-16 | Hoffmann-La Roche, Inc. | Galnac phosphoramidites, nucleic acid conjugates thereof and their use |
| CA2979703A1 (en) * | 2015-03-17 | 2016-09-22 | Arrowhead Pharmaceuticals, Inc. | Compositions and methods for inhibiting gene expression of factor xii |
| WO2016149020A1 (en) | 2015-03-17 | 2016-09-22 | Arrowhead Research Corporation | Rna interference agents |
| KR20180038465A (ko) * | 2015-08-07 | 2018-04-16 | 애로우헤드 파마슈티컬스 인코포레이티드 | Ｂ형 간염 바이러스 감염에 대한 ｒｎａｉ 치료법 |
| JOP20160211B1 (ar) * | 2015-10-01 | 2021-08-17 | Arrowhead Pharmaceuticals Inc | تراكيب وأساليب لتثبيط تعبير جيني للـ lpa |
| US10246709B2 (en) * | 2016-03-07 | 2019-04-02 | Arrowhead Pharmaceuticals, Inc. | Targeting ligands for therapeutic compounds |
| JP6989521B2 (ja) | 2016-09-02 | 2022-01-05 | アローヘッド ファーマシューティカルズ インコーポレイテッド | 標的化リガンド |
| UY37565A (es) * | 2017-01-10 | 2018-07-31 | Arrowhead Pharmaceuticals Inc | Agentes de iarn alfa-1 antitripsina (aat), composiciones que incluyen agentes de iarn aat y métodos de uso |
| EP3573623B1 (en) | 2017-01-30 | 2026-03-04 | Arrowhead Pharmaceuticals, Inc. | Compositions and methods for inhibition of factor xii gene expression |
-
2017
- 2017-03-07 US US15/452,423 patent/US10246709B2/en active Active
- 2017-03-07 CA CA3011946A patent/CA3011946A1/en active Pending
- 2017-03-07 MX MX2018009854A patent/MX2018009854A/es unknown
- 2017-03-07 TW TW110112971A patent/TWI783434B/zh active
- 2017-03-07 EP EP17763911.9A patent/EP3426261A4/en active Pending
- 2017-03-07 KR KR1020187027235A patent/KR102348425B1/ko active Active
- 2017-03-07 KR KR1020227000160A patent/KR102515329B1/ko active Active
- 2017-03-07 WO PCT/US2017/021175 patent/WO2017156012A1/en not_active Ceased
- 2017-03-07 BR BR112018068230-6A patent/BR112018068230B1/pt active IP Right Grant
- 2017-03-07 CN CN202110938247.8A patent/CN113797348A/zh active Pending
- 2017-03-07 TW TW106107454A patent/TWI727009B/zh active
- 2017-03-07 JO JOP/2017/0057A patent/JOP20170057B1/ar active
- 2017-03-07 AU AU2017229469A patent/AU2017229469B2/en active Active
- 2017-03-07 CN CN201780016137.8A patent/CN109069529B/zh active Active
- 2017-03-07 TW TW111137872A patent/TWI842117B/zh active
- 2017-03-07 IL IL296377A patent/IL296377A/en unknown
- 2017-03-07 JP JP2018547320A patent/JP6983797B2/ja active Active
- 2017-03-07 UY UY0001037146A patent/UY37146A/es active IP Right Grant
- 2017-03-07 KR KR1020237010168A patent/KR102830443B1/ko active Active
-
2018
- 2018-08-14 MX MX2023006332A patent/MX2023006332A/es unknown
- 2018-08-14 MX MX2023006334A patent/MX2023006334A/es unknown
- 2018-09-04 IL IL261598A patent/IL261598B/en unknown
-
2019
- 2019-03-25 US US16/363,108 patent/US20190211333A1/en not_active Abandoned
-
2021
- 2021-02-24 US US17/184,575 patent/US12116573B2/en active Active
- 2021-08-19 JO JOP/2021/0231A patent/JOP20210231A1/ar unknown
- 2021-11-23 IL IL288341A patent/IL288341B2/en unknown
- 2021-11-24 JP JP2021189879A patent/JP7485642B2/ja active Active
-
2023
- 2023-05-17 AU AU2023203102A patent/AU2023203102B2/en active Active
-
2024
- 2024-05-02 JP JP2024074913A patent/JP2024097862A/ja not_active Withdrawn
- 2024-09-04 US US18/824,808 patent/US20250243485A1/en active Pending
-
2025
- 2025-06-03 JP JP2025092644A patent/JP2025120251A/ja active Pending
- 2025-08-06 AU AU2025213612A patent/AU2025213612A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY37145A (es) | Ligandos de direccionamiento | |
| AR121312A2 (es) | AGENTES DE ARNi, COMPOSICIONES Y MÉTODOS DE USO DE LOS MISMOS PARA TRATAR ENFERMEDADES ASOCIADAS CON TRANSTIRETINA (TTR) | |
| CO2018003678A2 (es) | Composiciones y métodos para inhibir la expresión génica de lpa | |
| MX2024004433A (es) | Composiciones dirigidas. | |
| CY1119060T1 (el) | Ρυθμιστες ενζυμων μεθυλικης τροποποιησης, συνθεσεις και χρησεις αυτων | |
| ECSP20046463A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
| MX2015002409A (es) | Métodos y composiciones para el tratamiento de una afección genética. | |
| CO2018009275A2 (es) | Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub) | |
| UY40064A (es) | COMPOSICIONES DE ARNi DE SERPINA1 Y SUS MÉTODOS DE USO | |
| CU20170172A7 (es) | 4,6-diaminoquinolin-3-carbonitrilos sustituidos útiles como agentes analgésicos, antipiréticos o antiinflamatorios y antineoplásicos | |
| AR090906A1 (es) | Conjugados que contienen tetragalnac y procedimientos para la administracion de oligonucleotidos | |
| CL2015000829A1 (es) | Inhibidores de histona desmetilasas | |
| UY37272A (es) | Piridinas sustituidas con heteroarilo y métodos de uso | |
| MX2018004114A (es) | Compuestos terapeuticos y metodos. | |
| MX2019005898A (es) | Composiciones de arni de serpina 1 y sus métodos de uso. | |
| BR112019000693A2 (pt) | composições de muc1- car e métodos para uso | |
| CU20160006A7 (es) | Derivados de piperidinil-indol como inhibidores de factor de complemento b | |
| CL2018002291A1 (es) | Anticuerpos anti-fgfr2iiib afucosilados (divisional solicitud 201600221) | |
| CR20140079A (es) | Aminoquinazolinas como inhibidores de quinasa | |
| MX2009010103A (es) | Composiciones estructuradas que comprenden una arcilla. | |
| ECSP15032859A (es) | Derivados de n-(sustituido)-5-fluoro-4-imino-3-metil-2-oxo-3,4-dihidropirimidin-1(2h)-carboxilato | |
| ECSP15023182A (es) | Composiciones que comprenden vortioxetina y donepezilo | |
| UY34407A (es) | Nuevos moduladores de trpv3 | |
| CR20150148A (es) | Azaindolinas | |
| DOP2011000053A (es) | Agentes antifungicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 110 | Patent granted |
Effective date: 20240611 |